AREXVY is indicated for active immunization for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus in individuals 60 years of age and older.¹

Important Safety Information

- AREXVY is contraindicated in anyone with a history of a severe allergic reaction (eg, anaphylaxis) to any component of AREXVY
- Appropriate medical treatment and supervision must be available to manage possible anaphylactic reactions following administration of AREXVY

(continued on page 2)

Please see additional Important Safety Information throughout and accompanying full Prescribing Information for AREXVY.
What is RSV?
RSV is a common and contagious virus that usually causes mild, cold-like symptoms. But sometimes, RSV infection in older adults can progress to more severe disease involving the lower respiratory tract. Older adults are at increased risk for severe RSV infection, including those with certain underlying conditions.

What is AREXVY?
AREXVY is the first RSV vaccine approved for the prevention of RSV-LRTD in individuals aged 60 years and older.

How is AREXVY dosed and administered?
Please refer to the full Prescribing Information for AREXVY for comprehensive details.

AREXVY is supplied in 2 vials that must be reconstituted prior to administration. Administer 1 dose (0.5 mL) of AREXVY as an intramuscular injection.

Storage
AREXVY should be refrigerated. DO NOT FREEZE (discard if frozen)

Important Safety Information (cont.)
• Syncope (fainting) may occur in association with administration of injectable vaccines, including AREXVY. Procedures should be in place to avoid injury from fainting
(continued on page 3)

Please see additional Important Safety Information throughout and accompanying full Prescribing Information for AREXVY.

Safety and side effects
The most commonly reported adverse reactions were injection site pain, fatigue, myalgia, headache, and arthralgia.

The Key Points

- Symptomatic systemic reactions were mild
- The safety and tolerability profile of AREXVY was similar to placebo
- AREXVY is the first RSV vaccine approved for use in adults aged 60 years and older

Percentage of participants with solicited local and systemic adverse reactions within 4 days of vaccination in adults aged 60 years and older

<table>
<thead>
<tr>
<th>Local Adverse Reactions</th>
<th>AREXVY %</th>
<th>Placebo %</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pain, Any*</td>
<td>60.9</td>
<td>9.3</td>
</tr>
<tr>
<td>Pain, Grade 3</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>Erythema, &gt;20 mm</td>
<td>7.5</td>
<td>0.8</td>
</tr>
<tr>
<td>Erythema, &gt;100 mm</td>
<td>0.2</td>
<td>0</td>
</tr>
<tr>
<td>Swelling, &gt;20 mm</td>
<td>5.5</td>
<td>0.6</td>
</tr>
<tr>
<td>Swelling, &gt;100 mm</td>
<td>0.2</td>
<td>0</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Systemic Adverse Reactions</th>
<th>AREXVY %</th>
<th>Placebo %</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fatigue, Any*</td>
<td>33.6</td>
<td>16.1</td>
</tr>
<tr>
<td>Fatigue, Grade 3</td>
<td>1.7</td>
<td>0.5</td>
</tr>
<tr>
<td>Myalgia, Any*</td>
<td>28.9</td>
<td>8.2</td>
</tr>
<tr>
<td>Myalgia, Grade 3</td>
<td>1.4</td>
<td>0.3</td>
</tr>
<tr>
<td>Headache, Any*</td>
<td>27.2</td>
<td>12.6</td>
</tr>
<tr>
<td>Headache, Grade 3</td>
<td>1.3</td>
<td>0</td>
</tr>
<tr>
<td>Arthralgia, Any</td>
<td>18.1</td>
<td>6.4</td>
</tr>
<tr>
<td>Arthralgia, Grade 3</td>
<td>1.3</td>
<td>0.6</td>
</tr>
<tr>
<td>Fever, ≥38.0 °C/100.4 °F</td>
<td>2.0</td>
<td>0.3</td>
</tr>
<tr>
<td>Fever, &gt;39.0 °C/102.2 °F</td>
<td>0.1</td>
<td>0.1</td>
</tr>
</tbody>
</table>

N=exposed set for solicited safety set included all participants with at least 1 documented dose.
*Placebo was a saline solution.
*Any grade pain: Defined as any pain neither interfering with nor preventing normal everyday activities (Grade 1), painful when limbs is moved and interferes with everyday activities (Grade 2), or significant pain at rest and prevents normal everyday activities (Grade 3).
*Any grade fatigue, myalgia, headache, arthralgia: Defined as event easily tolerated (Grade 1), interfering with normal activity (Grade 2), or preventing normal activity (Grade 3).
*Temperature taken by any route (oral, axillary, or tympanic).
AE=adverse event; pIMD=potential immune-mediated disease; SAE=serious adverse event.

Study Design: Solicited AEs were evaluated in a subset of participants following a dose of AREXVY (n=879) or placebo (n=874). SAEs and pIMDs were monitored in all participants for 6 months following administration of AREXVY (n=12,467) or placebo (n=12,499), and AEs leading to deaths were monitored through the first analysis of Study 1. Similar rates of SAEs (4.2% vs 4.0%), deaths (0.4% vs 0.5%), and pIMDs (0.3% vs 0.3%) were reported between AREXVY and placebo, respectively.
Wondering what you can do to help?

When you see a customer aged 60 years or older, have them talk with a pharmacist about the risk of RSV, as well as vaccinating with AREXVY.¹²

Coding

Use the following code when billing AREXVY:

- **NDC: 10-dose carton** 58160-848-11

  For payers who require NDCs in an 11-digit format, please use: 58160-0848-11

  NDC=National Drug Code.

Important Safety Information (cont.)

- The most commonly reported adverse reactions (≥10%) were injection site pain (60.9%), fatigue (33.6%), myalgia (28.9%), headache (27.2%), and arthralgia (18.1%)

(continued on back cover)

Please see additional Important Safety Information throughout and accompanying full Prescribing Information for AREXVY.
Important Safety Information (cont.)

• Vaccination with AREXVY may not result in protection of all vaccine recipients

Please see additional Important Safety Information throughout and accompanying full Prescribing Information for AREXVY.

References:

Trademarks are owned by or licensed to the GSK group of companies.

©2023 GSK or licensor.
RSAOGM230095 June 2023
Produced in USA. 0002-0024-74